Fycompa 4 mg tablets contain perampanel, a selective non-competitive antagonist of the AMPA subtype of glutamate receptors used as an antiepileptic medication. By blocking AMPA receptor-mediated excitatory neurotransmission, perampanel reduces neuronal hyperexcitability associated with seizures. Fycompa is indicated as an adjunctive therapy for partial-onset seizures with or without secondary generalisation and for primary generalized tonic-clonic seizures in patients with epilepsy. The 4 mg strength provides an intermediate dose for patients who have titrated up from 2 mg and require greater seizure control.
To take Fycompa, swallow the tablet once daily at bedtime with or without food. Starting therapy typically involves initiating at 2 mg per day, followed by gradual weekly increments of 2 mg to reach 4 mg or higher based on clinical response and tolerability. Do not exceed the maximum recommended dose of 12 mg per day. If you miss a dose, take it as soon as you remember unless it is close to your next dose; do not double up. Do not stop taking Fycompa abruptly, as this may increase seizure frequency; consult your physician for a slow taper if discontinuation is necessary. Because perampanel is metabolised by the liver, dose adjustments may be needed in patients with hepatic impairment or those taking strong CYP3A4 inducers (such as carbamazepine, phenytoin, rifampicin).
Potential side effects include dizziness, somnolence, fatigue, irritability, headache, nausea, ataxia, weight gain, and falls. Serious adverse reactions may include mood or behavioural changes such as aggression, hostility, anger, agitation, paranoia, hallucinations, or suicidal ideation. Report any sudden mood or personality changes to a healthcare professional immediately. Use caution when driving or operating machinery until you know how the medication affects you. Pregnant or breastfeeding women should consult a doctor before using perampanel, as safety data are limited. If you have significant liver or kidney disease, discuss dose adjustments with your physician. For additional information or to purchase this medication, please visit: Fycompa 4 Mg.
To take Fycompa, swallow the tablet once daily at bedtime with or without food. Starting therapy typically involves initiating at 2 mg per day, followed by gradual weekly increments of 2 mg to reach 4 mg or higher based on clinical response and tolerability. Do not exceed the maximum recommended dose of 12 mg per day. If you miss a dose, take it as soon as you remember unless it is close to your next dose; do not double up. Do not stop taking Fycompa abruptly, as this may increase seizure frequency; consult your physician for a slow taper if discontinuation is necessary. Because perampanel is metabolised by the liver, dose adjustments may be needed in patients with hepatic impairment or those taking strong CYP3A4 inducers (such as carbamazepine, phenytoin, rifampicin).
Potential side effects include dizziness, somnolence, fatigue, irritability, headache, nausea, ataxia, weight gain, and falls. Serious adverse reactions may include mood or behavioural changes such as aggression, hostility, anger, agitation, paranoia, hallucinations, or suicidal ideation. Report any sudden mood or personality changes to a healthcare professional immediately. Use caution when driving or operating machinery until you know how the medication affects you. Pregnant or breastfeeding women should consult a doctor before using perampanel, as safety data are limited. If you have significant liver or kidney disease, discuss dose adjustments with your physician. For additional information or to purchase this medication, please visit: Fycompa 4 Mg.
0